相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2019
进行中（未招募）
1
25.0%
已完成
1
25.0%
招募中
1
25.0%
撤回
1
25.0%
暂无批准数据
- Biopharma companies raised a combined $1.7 billion in IPOs during the first quarter of 2026, the highest quarterly total since 2021. - The median biotech IPO raised $287.5 million, more than double the median seen in Q1 2025, though the number of offerings remained similar to recent years. - Nearly all companies that successfully priced an IPO had drugs in mid- or late-stage clinical testing, while preclinical companies have been shut out since 2024. - Macroeconomic factors, FDA leadership turnover, and potential competition from mega tech IPOs like SpaceX and OpenAI could constrain the biotech IPO window going forward.
- Genelux Corporation has appointed Dr. Jason Litten as Chief Medical Officer effective January 2, 2026, to oversee clinical development and medical strategy for the company's oncolytic immunotherapy pipeline. - Dr. Litten brings over 20 years of biopharmaceutical experience, including leadership roles at Chimeric Therapeutics, Artiva Biotherapeutics, and Amgen, with expertise in Phase 1-4 clinical trials across multiple cancer types. - The appointment comes as Genelux advances Olvi-Vec through pivotal milestones, including ongoing Phase 3 trials in platinum-resistant ovarian cancer and Phase 2 trials in non-small-cell lung cancer. - Dr. Litten received a stock option grant for 275,000 shares as part of his compensation package, reflecting the company's confidence in his ability to advance their oncolytic vaccinia virus platform.
- Artiva Biotherapeutics will present initial safety data from 32 autoimmune disease patients treated with AlloNK plus monoclonal antibody therapy, showing a favorable tolerability profile and feasibility for outpatient administration. - The company's translational data demonstrates uniform, deep B-cell depletion across all treated patients using high-sensitivity assays with 10- to 50-fold higher sensitivity than typical methods. - AlloNK is an allogeneic, off-the-shelf NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity for B-cell depletion in autoimmune diseases including rheumatoid arthritis and Sjögren's disease.
- Artiva Biotherapeutics received FDA Fast Track Designation for AlloNK with rituximab to treat refractory rheumatoid arthritis, a condition affecting over 100,000 treatment-resistant patients in the United States. - The company plans to share patient safety data in November 2024 and expects to release clinical response data from more than 15 refractory RA patients in the first half of 2026. - Over 20 patients have been tested with AlloNK plus antibody therapy across autoimmune trials, including rheumatoid arthritis and lupus, with safety data highlighting tolerability and ease-of-use. - Following the FDA announcement, Artiva's stock surged 105% in pre-market trading, with analysts maintaining a Strong Buy consensus rating and an average price target of $14.50.
- Artiva Biotherapeutics received FDA Fast Track Designation for AlloNK in refractory rheumatoid arthritis, marking the first drug candidate in the deep B-cell depleting category to achieve this milestone. - The company has prioritized refractory RA as its lead indication, targeting over 100,000 treatment-refractory patients in the United States who could benefit from deep B-cell depleting therapy. - More than 20 patients have been treated with AlloNK plus monoclonal antibody therapy across multiple autoimmune diseases, with safety and translational data expected in mid-November 2025. - AlloNK's off-the-shelf format and outpatient administration capability could address accessibility challenges faced by other deep B-cell depleting therapies like CAR-T and T-cell engagers.
- DelveInsight's 2025 pipeline report reveals over 35 companies are actively developing more than 40 investigational therapies for lupus nephritis treatment. - Hoffmann-La Roche leads with obinutuzumab in Phase III trials, while other promising candidates include ADX-097 from Q32 Bio and NKX019 from Nkarta Therapeutics. - The FDA granted Fast Track designation to AlloNK from Artiva Biotherapeutics in February 2024 for combination therapy with rituximab or obinutuzumab. - Lupus nephritis affects patients with systemic lupus erythematosus and can progress to chronic kidney disease or end-stage renal disease without effective treatment.
- Artiva Biotherapeutics reported longer-term Phase 1/2 data for AlloNK cell therapy, demonstrating prolonged durability of response in patients with non-Hodgkin lymphoma. - The combination therapy of AlloNK with rituximab showed promising efficacy and safety profiles, potentially offering a new treatment option for patients with relapsed or refractory lymphoma. - Results highlight AlloNK's potential as an off-the-shelf NK cell therapy that could address limitations of current cellular immunotherapies while maintaining clinical effectiveness.
- Artiva Biotherapeutics' AlloNK in combination with rituximab demonstrated a 64% complete response rate in heavily pretreated B-cell non-Hodgkin lymphoma patients, comparable to approved autologous CAR-T therapies. - The median duration of response has not been reached and extends beyond 19.4 months, with a well-tolerated safety profile showing no cytokine release syndrome or neurotoxicity events. - Results suggest AlloNK's potential for deep B-cell depletion in autoimmune diseases, with a safety profile compatible with outpatient administration in community settings.
• GC Cell has initiated first patient dosing in a Phase 1 clinical trial of GCC2005, a novel CD5 CAR-NK cell therapy targeting relapsed or refractory NK and T-cell malignancies, addressing a significant unmet need in aggressive lymphomas. • The innovative therapy utilizes allogeneic umbilical cord blood-derived NK cells engineered with a CD5-targeting chimeric antigen receptor and IL-15 co-expression to enhance persistence and anti-tumor efficacy. • The trial will enroll approximately 48 patients to evaluate safety, tolerability, maximum tolerated dose, and recommended Phase 2 dose, with promising preclinical data suggesting potential as a first-in-class treatment option.
• Artiva Biotherapeutics has received FDA Fast Track designation for AlloNK therapy in autoimmune diseases, potentially accelerating development through enhanced agency communication and rolling application options. • The company is conducting two clinical trials: a company-sponsored study focusing on lupus patients and an investigator-initiated trial exploring lupus, rheumatoid arthritis, pemphigus vulgaris, and vasculitis. • AlloNK's novel mechanism combines traditional monoclonal antibodies with allogeneic NK cells, positioning it between conventional B-cell depletion therapies and engineered CAR-T approaches for autoimmune conditions.
